**Appendix No. 4 - Number of all cancer patients and newly diagnosed cancer patients treated in the cancer center**

|  |  |  |
| --- | --- | --- |
|  | 1 | 2 |
| Disease site (without pediatric tumors) according to the list of tumor localizations used in the analysis of the Robert Koch Institute ('Krebs in Deutschland; 2013) modified on the basis ofthe National Cancer Certification Program 2015 | ICD-10 Code | Number of all cancer patients treated in the cancer center in 2016 | Number of cancer patients newly diagnosed in 2016 |
| **A.** |
| *Head and Neck***Stoma/Pharynx** |  |
| C00-14 |  |  |
| **Larynx** | C32 |  |  |
| *Upper GI Tract***Esophagus**  |  |
| C15 |  |  |
| **Stomach**  | C16 |  |  |
| **Intestine** | C18-21 |  |  |
| *Liver/Gall Bladder***Liver**  |  |
| C22 |  |  |
| **Gall Bladder** | C23-24 |  |  |
| **Pancreas**  | C25 |  |  |
| **Lung**  | C33-34 |  |  |
| **Malignant Melanoma**  | C43 |  |  |
| **Bone, Articular Cartilage, Connective and Soft Tissue** | C40-41, C45-49 |  |  |
| *Breast/DCIS***Ductal Carcinoma in Situ (DCIS)** |  |
| D05 |  |  |
| **Breast** | C50 |  |  |
| **Vulva** | C51 |  |  |
| **Cervix** | C53 |  |  |
| **Uterus** | C54-55 |  |  |
| **Ovary**  | C56 |  |  |
| **Prostate**  | C61 |  |  |
| **Testes**  | C62 |  |  |
| **Kidney**  | C64 |  |  |
| **Urinary Bladder** | C67 |  |  |
| **Central Nervous System** | C70-72**\*** |  |  |
| **Thyroid** | C73 |  |  |
| **Morbus Hodgkin** | C81 |  |  |
| **Non-Hodgkin Lymphomas** | C82-85 |  |  |
| **Plasmocytoma** | C90 |  |  |
| **Leukemias** | C91-95 |  |  |
| **Other Hematological Malignancies** | C86-88, C96 |  |  |
| **TOTAL (A.)** |  |  |  |
| **B.** |
| **Others\*\* (Examples):** |  |  |  |
| Other Malignant Neoplasms of the Skin | C44 |  |  |
| Pediatric Tumors (Patients < 18 y.)**\*\*\*** |  |  |  |
| **TOTAL (A. + B.)** |  |  |  |

**Column 1: Number of all cancer patients treated in the cancer center in 2016.** Reflect the number of patients coming to the cancer center, not the number of visits. A patient is to be counted for the year 2016, if he/she was treated for a principal diagnosis of cancer between 1 January and 31 December 2016. Do not include any patient more than once unless they have been treated for two malignancies in 2016. All patients should be counted regardless of whether they have a newly diagnosed cancer or have recurrent disease or newly appeared metastases and were referred to the cancer center for further evaluation and primary or secondary treatment. This category excludes consults (e.g., for service or second opinions), diagnoses at autopsy, and former patients admitted for rehabilitation purposes or treatment of some other conditions. It also excludes patient follow-up activities after treatment is completed.

**Column 2: Number of patients newly diagnosed in the cancer center or elsewhere in 2016 which were treated in the cancer center.** Reflect the number of patients coming to the cancer center, not the number of visits. Generally a patient is to be counted as 'newly diagnosed' for the year 2016, if the incidence date (according to the 'Recommendations for Coding Incidence Date' of the European Network of Cancer Registries - ENCR) was in 2016. Do not include any patient more than once unless he/she had two malignancies diagnosed in one year. Do not include patients with recurrent disease. Definition of 'patients treated in the cancer center': therapy planning and the main part of the therapy take place in the cancer center.

\*Further CNS tumors which are requested within the 'National Cancer Certification Program' ('Erhebungsbogen Neuroonkologische Tumoren', Chapter 1.2.1; ICD-10: C75.1-3, D32, D33.3, D35.2-4; primary CNS lymphomas) can be listed under 'Others'.

\*\*Disease sites which are not listed above, can be indicated under 'Others', but must not be counted among 'Total' (A).

\*\*\*Pediatric tumors may only be listed here and must not be counted under 'Total' (A).